This bill matters because it addresses a significant barrier to getting affordable medications to patients: 'method of use' patents. Currently, even if a drug has many uses, and only some are patented, generic and biosimilar companies often face costly and time-consuming lawsuits if they try to market their version for only the unpatented uses. This can delay the availability of cheaper alternatives, keeping drug prices high.

If this bill becomes law, it would provide a clear legal pathway for generic and biosimilar versions of drugs to enter the market for unpatented uses without the constant threat of patent infringement lawsuits. This change is expected to foster greater competition, potentially leading to lower drug costs for consumers and the healthcare system. If it doesn't become law, the existing legal challenges and delays for generic and biosimilar products are likely to continue, potentially slowing down access to more affordable medicines.